Tether, the company behind the world's dominant stablecoin, has quietly built a balance sheet rivaling major financial institutions, amassing vast holdings of U.S. Treasury debt and gold. Its explosive growth is reshaping its role in traditional finance and drawing regulatory scrutiny.
Shareholders in Harley-Davidson's electric motorcycle spinoff, LiveWire Group, have seen their holdings erode dramatically over five years, with a recent $55 million weekly loss adding to the pain. The company's ongoing revenue contraction raises fundamental questions about its path to profitability in the competitive EV market.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.
Former UK ambassador to Washington, Peter Mandelson, faces intensifying political and public pressure to relinquish his lifetime seat in the House of Lords following new revelations about his financial and personal ties to the late convicted sex offender Jeffrey Epstein. Prime Minister Keir Starmer has called for his resignation, as documents suggest payments and close correspondence between the two.
MarketAxess Holdings (MKTX), once a high-flying fintech darling, has seen its share price erode by nearly 70% over five years. As the bond trading platform grapples with shifting market dynamics and increased competition, investors are left debating whether the current valuation presents a rare buying opportunity or signals deeper structural challenges.
Oracle is launching a massive $45-$50 billion capital raise to aggressively expand its cloud infrastructure, fueled by long-term contracts with AI giants like OpenAI, NVIDIA, and Meta. The move underscores the fierce competition in the cloud arms race, even as the company's stock faces recent headwinds.
With pharmaceutical companies increasingly deploying AI in direct-to-consumer platforms, the regulatory landscape remains fragmented. In the absence of comprehensive federal action, states are stepping in with disparate laws to address privacy and safety concerns, creating a complex compliance challenge for the industry.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
PGIM India Asset Management, the underperforming local arm of the U.S. financial giant, has drawn acquisition interest from domestic rivals Groww and Edelweiss as its parent considers an exit from the competitive market.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Despite a brutal 50% share price plunge over three months, Reitar Logtech Holdings (NASDAQ:RITR) exhibits underlying financial resilience. While its Return on Equity appears weak, the company's aggressive reinvestment strategy has fueled a remarkable 26% net income growth over five years, starkly outperforming its struggling industry. This analysis delves into the disconnect between short-term market sentiment and the firm's long-term operational engine.
BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
BitMine Immersion Technologies (NYSEAM:BMNR) is navigating a turbulent period marked by over $6 billion in unrealized losses from its concentrated Ethereum holdings and the abrupt departure of its president. The company's aggressive crypto treasury strategy and governance decisions are now under the microscope.
A recent revision to RenaissanceRe Holdings' official price target has refocused market attention on the reinsurer, highlighting how evolving analyst assumptions—rather than a specific number—are reshaping the investment narrative around the stock.
TKO Group Holdings' UFC has secured a new, multi-year marketing partnership with Good Greek Moving & Storage. The agreement will feature brand integration across UFC Fight Nights, Dana White's Contender Series, and athlete ambassador campaigns, signaling a continued push to monetize its combat sports audience beyond traditional media rights.
While market volatility tests many sectors, Hilton Worldwide Holdings has charted a remarkable course. Shareholders have seen total returns near 169% over five years, a performance fueled by a return to profitability and strategic execution that outpaced broader market trends.
Nominee Kevin Warsh's desire to aggressively shrink the Federal Reserve's multi-trillion dollar holdings collides with a financial system now structurally dependent on ample liquidity, making rapid contraction a high-risk endeavor, analysts say.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
